OHE Publications

OHE releases a number of publications throughout the year, authored by OHE team members and/or outside experts. All are free for download as pdf files; hard copies of some publications are available upon request.

A description of the OHE publications categories.


 

Feng, Y., Devlin, N., Shah, K., Mulhern, B. and Van Hout, B.

 

Research Paper
January 2016

Please note that a revised version of this paper has been accepted for publication and is forthcoming in Health Economics. There are some differences between the value set reported in the Health Economics version and the provisional value set reported in the OHE Research Paper version. Any use of the content of these materials is the sole responsibility of the user.

Devlin, N., Shah, K., Feng, Y., Mulhern, B. and Van Hout, B.

Research Paper
January 2016

Please note that a revised version of this paper has been accepted for publication and is forthcoming in Health Economics. There are some differences between the value set reported in the Health Economics version and the provisional value set reported in the OHE Research Paper version.

Sussex, J. and Hernandez-Villafuerte, K.

Research Paper
December 2015

This paper presents a model to capture the behaviour of health sector decision makers when making resource allocation decisions on the level and mix of healthcare production, while taking into consideration the maximum expenditure (budget) allowed by the government or the health system regulator.

The paper seeks to address two perennial policy and practical discussions in the UK National Health Service (NHS) (and elsewhere): how to cope with financial austerity; and the opportunity costs of reimbursing new health technologies.

Marsden, G. and Mestre-Ferrandiz, J.

Research Paper
November 2015

This OHE Research Paper provides an overview of the current dementia R&D landscape. The research was undertaken by OHE for Imperial College and the UK Department of Health.

Pistollato, M.

Research Paper
August 2015

Why might the launch price of a new drug be a poor indicator of future expenditure for a drug? Which are the factors that determine the future prices and market shares of a drug? Understanding the answers to these questions can be crucial when conducting cost-effectiveness analyses i.e. when studying if it is desirable to publicly fund reimburse a new drug. This paper models and studies the price of a new drug along its life-cycle, from launch to discontinuation, to understand how the price of the drug evolves and to help inform cost-effectiveness evaluations.

Papadimitropoulos, M., Elbarazi, I., Blair, I., Katsaiti, M.S., Shah, K. and Devlin, N.

Research Paper
February 2015

No EQ-5D-5L value sets are currently available in the Middle East to inform decision making in the region’s health care systems. This study tests the feasibility of eliciting EQ-5D-5L values from a general public sample in the United Arab Emirates (UAE) using the EuroQol Group’s standardised valuation protocol.

Parkin, D., Devlin, N. and Feng, Y.

Research Paper
August 2014

The EQ-5D is one of the most used health-related quality of life instruments worldwide. Understanding the characteristics of its underlying data is essential. In this paper, OHE’s Nancy Devlin and Yan Feng join David Parkin from King’s College London in analyzing characteristics of the EQ-5D indexing process that may obscure useful, and important, information about health states.

Shah, K., Sussex, J., Hernandez-Villafuerte, K. and Garau, M., Rotolo, D., Hopkins, M.M., Grassano, N., Crane, P., Lang, F., Hutton, J., Pateman, C., Mawer, A., Farrell, C. and Sharp, T.

Research Paper
July 2014

As earlier OHE research has demonstrated, sources of funding for medical research—public, charity and private sector—are complementary, not duplicative. The three sectors also differ in their approaches. As a result, decreased funding from one would not only reduce the overall financing available, but also change the nature of the research effort overall. This is a concern given that austerity in government spending in the UK is likely to continue for some time. This report produced by OHE and SPRU at the University of Sussex for Cancer Research UK explores two sets of questions: 1.

Karlsberg Schaffer, S., Sussex, J., Hughes, D. and Devlin, N.

Research Paper
June 2014

This new research from the OHE examines how Local Health Boards (LHBs) in Wales adjust spending to meet the statutory requirement of providing access to technologies recommended by NICE within three months after NICE publishes a Technology Appraisal (TA). Based on interviews with medical and/or finance directors of the seven Wales LHBs, the study covers the period from October 2010 through March 2013.

Pages